WEED, Inc. Reports Continued Losses and No Revenue in Q2 2025

WEED, Inc. reported its financial results for the second quarter of 2025, revealing a continued lack of revenue and significant operational losses. The company recorded a net loss of $107,616 for the three months ending June 30, 2025, compared to a net loss of $110,953 for the same period in 2024. For the six months ended June 30, 2025, the net loss increased to $548,071 from $281,605 in the prior year. The absence of revenue remains a critical issue, as the company has not generated any sales since its inception.

Operating expenses for the second quarter of 2025 totaled $94,045, a decrease from $144,955 in the same quarter of 2024. This reduction was primarily driven by lower general and administrative expenses, which fell to $64,052 from $85,296, and a decrease in professional fees from $51,474 to $24,372. Despite these reductions, the company’s total operating expenses for the first half of 2025 rose to $528,782, up from $315,008 in the previous year, largely due to increased general and administrative costs.

In terms of financial position, WEED, Inc. reported total assets of $548,906 as of June 30, 2025, down from $738,366 at the end of 2024. The decline in assets was primarily attributed to a significant drop in cash reserves, which fell to $5,350 from $159,355. Current liabilities also increased slightly to $996,833 from $959,372, reflecting ongoing financial pressures. The company’s accumulated deficit reached $85,451,350, raising concerns about its ability to continue as a going concern without securing additional financing.

Strategically, WEED, Inc. has been focusing on expanding its operations in the cannabis sector, including plans for research and product development in both the medical and recreational cannabis markets. The company has made acquisitions, such as Hempirical Genetics, LLC, to enhance its capabilities in cannabis research. However, the company has indicated that it requires further capital to advance its initiatives, including the Cannabis Genomic Study and potential entry into the hemp and infused beverage markets.

Looking ahead, WEED, Inc. remains optimistic about its long-term goals, which include becoming a comprehensive "Seed-to-Sale" company in the cannabis industry. The management is actively pursuing new funding sources to support its operations and strategic initiatives. However, the company acknowledges the challenges it faces in achieving these objectives, particularly in light of its current financial situation and the need for significant capital investment.